Global Journal of Medical Research, A: Neurology & Nervous System, Volume 23 Issue 3

67. Binder MR. Psychiatric and functional physical symptoms: The more telling “fifth” vital sign. AJCEM 2021; 9 (6): 233-337. 68. Binder MR. Neuronal hyperexcitability: The elusive but modifiable instigator of disease. AJCEM 2022; 10 (1): 1-7. 69. Gabapentin—The popular but controversial anticonvulsant drug may be zeroing in on the pathophysiology of disease. AJCEM 2021; 9 (4): 122-134. 70. Rose GM, Diamond DM, Pang K, Dunwiddie TV. Primed burst potentiation: lasting synaptic plasticity invoked by physiologically patterned stimulation. In: Haas HL, Buzsàki G. (eds) Synaptic plasticity in the hippocampus. Springer, Berlin, Heidelberg, 1988. 71. Khushboo SB. Antidepressants: mechanism of action, toxicity and possible amelioration. J Appl Biotechnol Bioeng 2017; 3 (5): 437-448. 72. Khedr EM, Elserogy Y, Fawzy M. Effects of psychotropic drugs on cortical excitability of patients with major depressive disorders: A transcranial magnetic stimulation study. Psychiatry Research 2020; 291: 113287. 73. Cooper DC, Moore SJ, Staff NP, Spruston N. Psychostimulant-induced plasticity of intrinsic neuronal excitability in ventral subiculum. J Neurosci 2003; 23 (30): 9937-9946. 74. Cleare A, Pariante CM, Young AH, et al. Evidence- based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol2015; 29 (5): 459-525. 75. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 4:73-79. 76. Kahn DA, Sachs GS, Printz DJ, Carpenter D. Medication treatment of bipolar disorder 2000: A summary of the expert consensus guidelines. Journal of Psychiatric Practice 2000; 6 (4): 197-211. 77. Binder MR.A pathophysiolgically-based approach to the treatment and prevention of mental illness and its related disorders. AJCEM 2021; 9 (6): 223-232. 78. Binder MR. Focused neuroregulation in the treatment and prevention of mental and physical illness. AJCEM 2022; 10 (2): 49-58. 79. Binder MR. Introducing the term “neuroregulator” in Psychiatry. AJCEM 2019; 7 (3): 66-70. 80. Fergusson D, Doucette S, Glass KC,et al. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ 2005; 330: 396-402. 81. Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: A meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 2016; 85 (3): 171-179. 82. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006; 163 (5): 813-821. 83. Healy D. Let the eat prozac: The unhealthy relationship between the pharmaceutical industry and depression. New York: University Press; 2004. 84. Britton JW, Shih JJ. Antiepileptic drugs and suicidality. Drug, Healthcare and Patient Safety 2010; 2: 181-189. 85. Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. Intestinal absorption study: Challenges and absorption enhancement strategies in improving oral drug delivery. Pharmaceuticals (Basel) 2022; 15; (8): 975. 86. Lopresti AL. The Effects of psychological and environmental stress on micronutrient concentrations in the body: A review of the evidence. Adv Nutr 2020; 11 (1): 103-112. 87. Banks W. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 2016; 15 (4):275–92. 88. Lo C, Nguyen S, Yang C, et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci 2020; 13 (5): 861-870. 89. Olafuyi O, Parekh N, Wright J, Koenig J. Inter ‐ ethnic differences in pharmacokinetics—is there more that unites than divides? Pharmacol Res Perspect 2021; 9(6): e00890. 90. Binder MR. Symptom instability as a predictor of response to mood stabilizers: A retrospective chart review of 300 consecutive inpatients and outpatients with symptoms of depression. 2005 (unpublished study). 91. Grunze HCR. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci2008; 10: 77-89. 34 Year 2023 Global Journal of Medical Research Volume XXIII Issue III Version I ( D ) A © 2023 Global Journals A Precision Medicine Approach to the Treatment of Psychiatric Disorders